Duchenne's muscular dystrophy
- Duchenne muscular dystrophy
- Pseudohypertrophic muscular dystrophy
- Duchenne-Aran dystrophy
Nature
Duchenne muscular dystrophy (DMD) has its onset in early childhood, at about 2 to 6 years. The symptoms are generalized weakness and muscle wasting affecting the limb and trunk muscles first. Calves often enlarged. The disease progresses slowly but will affect all voluntary muscles. Survival is rare beyond late twenties.
Claim
Duchenne's muscular dystrophy (DMD) is a critical health issue that demands urgent attention. This devastating genetic disorder not only robs children of their mobility but also significantly shortens their lives, placing immense emotional and financial burdens on families. The lack of effective treatments and the slow pace of research funding highlight a glaring injustice in healthcare. We must prioritize DMD awareness, research, and support to improve the lives of those affected and ultimately find a cure.
Counter-claim
Duchenne's muscular dystrophy (DMD) is often overstated as a critical issue. While it affects a small population, the broader societal impact is minimal compared to more prevalent health crises. Resources and attention should focus on widespread diseases that affect millions, rather than a rare condition that, despite its challenges, represents a fraction of the healthcare landscape. Prioritizing DMD distracts from addressing urgent public health needs that truly affect the majority.
Broader
Narrower
Related
SDG
Metadata
Database
World problems
Type
(G) Very specific problems
Biological classification
N/A
Subject
Medicine » Locomotive, integumentary system
Medicine » Muscular system » Muscular system
Content quality
Presentable
Language
English
1A4N
J0080
DOCID
12000800
D7NID
146942
Last update
Oct 4, 2020